Also Read | Anant Ambani, Nita Ambani’s fitness trainer reveals if working out on empty stomach is helpful for fat loss or harmful

Robert Love, a neuroscientist specializing in Alzheimer’s prevention, has highlighted three weight loss supplements, breaking down how each one works. In an Instagram video posted on September 18, he explained the underlying mechanisms of these supplements and the physiological processes they activate to support fat burning, offering a clearer understanding of how they may influence the body.

5-HTP

5-HTP or tryptophan is often prescribed for anxiety and depression, but according to Robert, it can also be used as a weight loss supplement. He explains, “A lot of people engage in emotional eating and people engage in emotional eating often when they’re stressed, or they’re anxious, or they are depressed.” 5-HTP is a precursor to the neurotransmitter serotonin, which is also termed as the happy hormone, and is a chief constituent of several anti-anxiety and anti-depressant drugs. The neuroscientist emphasises, “5-HTP is a much safer, more natural way to increase your serotonin levels. And by boosting your serotonin, with either 5HTP or tryptophan, this can help reduce depression, anxiety, and stress, and help reduce emotional eating.”

Psyllium husk

Robert says that psyllium husk is essentially a rich source of fibre for your gut bacteria. It feeds your gut bacteria and helps you feel more full. The neuroscientist states, “If you have psyllium husk in a drink of water, for example, or some other liquid, 30 to 60 minutes before a meal, you’re going to be less hungry and your gut bacteria are going to be satisfied.” He also adds that psyllium husk is great for initiating bowel movements, due to its high fibre content. It is an inexpensive way to reduce appetite and support weight loss.

Also Read | Neuroscientist says ‘eat this immediately before meals to lose weight’; reveals surprising health benefits

EGCG

Epigallocatechin-3-gallate (EGCG) is a powerful polyphenol and the most abundant catechin in green tea, widely linked to its numerous health benefits. According to Robert, it helps in weight loss by oxidising and burning fat, while also increasing metabolism. He adds that it is fantastic for the brain as well. As per research from Japan, the neuroscientist states, “Those who drink two cups of green tea or more a day, have significant reduction in their symptoms of dementia.” So EGCG is a multi-purpose supplement that also supports weight loss. Robert additionally suggests, “You could also drink green tea or my favorite is, you can have matcha. Matcha is approximately 10 times more beneficial for your brain than green tea.”

Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. It is based on user-generated content from social media. HT.com has not independently verified the claims and does not endorse them.

Dublin, Sept. 19, 2025 (GLOBE NEWSWIRE) — The “U.S. Clinical Nutrition Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034” report has been added to ResearchAndMarkets.com’s offering.

The U.S. Clinical Nutrition Market was valued at USD 14.7 billion in 2024 and is estimated to grow at a CAGR of 10.1% to reach USD 37.4 billion by 2034.

The industry is undergoing a significant transformation driven by a surge in chronic health conditions, an aging population, and the growing preference for at-home care services. These shifts have highlighted the need for personalized nutrition plans that enhance treatment results and accelerate patient recovery. Older adults face higher risks of malnutrition due to appetite changes, chronic illness, and metabolic alterations, which fuel demand for condition-specific nutritional solutions. As nutritional science evolves, clinical nutrition is becoming a vital component in patient recovery where conventional diets are insufficient, pushing interest toward targeted, individualized options and lifting market growth.

Clinical nutrition is specifically designed to support patients managing long-term health conditions. Increasing focus from regulatory bodies on nutrition security and continued innovation in home-use and condition-targeted formulas are contributing to long-term market development. The rising number of premature births and increasing needs in infant nutrition have also played a crucial role in propelling the market forward.

In 2024, the infant nutrition segment generated USD 8.3 billion, driven by rising awareness around early developmental needs. Parents are increasingly focused on nutritional adequacy during infancy to support brain and physical development. Growing cases of dietary sensitivities and health conditions in newborns, along with significant innovation in formulas fortified with DHA, probiotics, and other vital nutrients, have enhanced product appeal and demand.

The pediatric segment held a 59.7% share in 2024, reflecting a sharp rise in nutritional solutions tailored for children. Increased prevalence of early-life health concerns and the rising importance of nutrition in supporting immune health and cognitive growth are central to this expansion. Parents’ awareness around child-specific nutrition fuels demand for high-quality clinical nutrition products. At the same time, government-supported programs focused on pediatric wellness continue to drive strong uptake.

The offline distribution channels segment generated USD 12.4 billion in 2024. This segment, including hospital and retail pharmacies, maintains a strong market position due to trusted access points within healthcare environments. Healthcare practitioners commonly prescribe and distribute clinical nutrition products directly through hospital systems, strengthening consumer confidence. Traditional in-person consultations, reliable supply, and immediate product availability make offline methods the preferred purchasing route, especially for ongoing care.

Major industry players shaping the U.S. Clinical Nutrition Market include Nestle Health Science, BASF, Hero Nutritionals, Hormel Foods, Perrigo, Danone, Meiji Holdings, Abbott (Abbott Nutrition), Grifols, Aculife Healthcare, Fresenius Kabi, Baxter, B Braun, and Mead Johnson (Reckitt Benckiser).

Leading players are expanding their presence by introducing disease-specific formulations and investing in product innovations that target diverse patient populations. Companies are focusing on fortifying products with essential nutrients like omega fatty acids, amino acids, and probiotics to address both pediatric and geriatric needs. Strategic collaborations with healthcare providers and hospital networks are enhancing distribution and brand credibility. Many firms are strengthening their home care portfolios to cater to the growing shift toward at-home treatments.

Key Attributes:

Key Topics Covered:

Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.3 Data mining sources
1.4 Base estimates and calculations
1.5 Primary research and validation
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
2.2 CXO perspectives: Strategic imperatives
2.2.1 Key decision points for industry executives
2.2.2 Critical success factors for market players
2.3 Future outlook and strategic recommendations

Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of chronic diseases
3.2.1.2 High incidence of malnutrition
3.2.1.3 Advancements in nutritional science
3.2.1.4 Shift toward home healthcare
3.2.2 Industry pitfalls and challenges
3.2.2.1 High cost of advanced formulations
3.2.2.2 Limited reimbursement policies
3.2.3 Market opportunities
3.2.3.1 Growing shift towards personalized nutrition solutions
3.2.3.2 Demand for plant-based and allergen-free products
3.2.3.3 Technological integration
3.3 Growth potential analysis
3.4 Technology landscape
3.4.1 Current technological trends
3.4.2 Emerging technologies
3.5 Supply chain analysis for clinical nutrition
3.6 Dietary supplements usage scenario in U.S.
3.7 Pipeline analysis
3.8 Regulatory landscape
3.9 Future market trends
3.10 Porter’s analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Key developments
4.5.1 Merger and acquisition
4.5.2 Partnership and collaboration
4.5.3 New product launches

Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
5.1 Key trends
5.2 Infant nutrition
5.2.1 Milk-based
5.2.2 Soy-based
5.2.3 Organic formula
5.2.4 Other infant nutrition
5.3 Enteral nutrition
5.3.1 Standard composition
5.3.2 Disease specific composition
5.3.3 Elemental formulas
5.3.4 Other enteral nutrition
5.4 Parenteral nutrition
5.4.1 Amino acids
5.4.2 Fats
5.4.3 Carbohydrates
5.4.4 Vitamins and minerals
5.4.5 Other parenteral nutrition

Chapter 6 Market Estimates and Forecast, by Consumer, 2021-2034 ($ Mn)
6.1 Key trends
6.2 Pediatric
6.3 Adult

Chapter 7 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
7.1 Key trends
7.2 Malnutrition
7.3 Cancer nutrition
7.4 Metabolic disorders
7.5 Neurological diseases
7.6 Gastrointestinal disorder
7.7 Other applications

Chapter 8 Market Estimates and Forecast, by Dosage Form, 2021-2034 ($ Mn)
8.1 Key trends
8.2 Powder
8.3 Liquid
8.4 Solid

Chapter 9 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
9.1 Key trends
9.2 Offline channels
9.2.1 Hospital pharmacies
9.2.2 Retail pharmacies
9.2.3 Other offline channels
9.3 Online channels

Chapter 10 Company Profiles
10.1 Abbott (Abbott Nutrition)
10.2 Aculife Healthcare
10.3 B Braun
10.4 BASF
10.5 Baxter
10.6 Danone
10.7 Fresenius Kabi
10.8 Grifols
10.9 Hero Nutritionals
10.10 Hormel Foods
10.11 Mead Johnson (Reckitt Benckiser)
10.12 Meiji Holdings
10.13 Nestle Health Science
10.14 Perrigo

For more information about this report visit https://www.researchandmarkets.com/r/wa7xm5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

• U.S. Clinical Nutrition Market

A common, over-the-counter form of vitamin B3 has emerged as an inexpensive ally in protecting us from skin cancer, lowering the risk by an average of 14% and increasing to a massive 54% for anyone who has previously had a positive diagnosis. This latest study of more than 33,000 patients supports earlier evidence that emerged in a 2015 Australian trial.

Researchers from Vanderbilt University Medical Center conducted a large real-world analysis of US veterans, which looked at the health records of 33,822 individuals, comparing those prescribed niacinamide (typically 500 mg twice daily for more than 30 days) with matched patients who didn’t take it.

Overall, niacinamide – also known as nicotinamide, a vitamin B3 form found in food and supplements that supports cellular energy, DNA repair and healthy skin – was associated with a 14% lower risk of developing skin cancer. When people began nicotinamide after having earlier received a positive skin cancer diagnosis, the reduction in risk was 54%. What’s more, the effect was seen in both basal cell carcinoma and cutaneous squamous cell carcinoma, with the largest drop in squamous cell cancers.

“There are no guidelines for when to start treatment with nicotinamide for skin cancer prevention in the general population,” said corresponding author Lee Wheless, M.D., assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center. “These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier. We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers.”

While basal cell carcinoma, which generally affects areas of the skin that have endured longterm exposure to the Sun, develops slowly, they can be easily missed for some time and surgery can be significant. (In 2024, I had surgery to remove one measuring 0.4 cm in diameter, which required a deep and wide excision, and around 20 subcutaneous and surface stitches.) Cutaneous squamous cell carcinoma, meanwhile, are cancerous growths on a more surface layer of skin. These, along with melanoma, make up the three malignant skin cancers.

People tend to underestimate the impact and seriousness of non-melanoma cancers. The US spends more than US$8 billion each year in treating skin cancer – and a majority of that cost ($4.8 billion) is to address non-melanoma types.

In general, niacinamide has been shown to help skin cells repair UV-induced DNA damage, and it blunts some of the immunosuppressive effects of sunlight. While observational, so causation can’t be proven, this study is by far the biggest dataset yet on niacinamide’s everyday performance outside of controlled clinical trials. The veteran cohort also skews older and male (average age 77 and predominantly white men), and the researchers caution that studies on a more diverse demographic are needed to see if these results can be replicated more broadly.

However, it does echo the findings of the groundbreaking 2015 ONTRAC phase-3 trial in Australia, which demonstrated that 500 mg of niacinamide twice daily lowered the incidence of new non-melanoma skin cancers by about 23% over 12 months in 386 high-risk adults with prior skin cancers. And this protective factor diminished once the individuals discontinued the treatment.

While the researchers urge that this is no replacement for covering up and applying sunscreen to exposed skin, for people who’ve had a first basal or squamous cell carcinoma removed, a daily niacinamide regimen is emerging as a practical, inexpensive way to lower the odds of a recurrence. And this study gives clinicians and patients more real-world numbers to weigh when deciding whether these supplements could be of benefit.

“The results of this cohort study suggest that there is a decreased risk of skin cancer among patients treated with nicotinamide, with the greatest effect seen when initiated after the first skin cancer,” noted the researchers.

“Nicotinamide, a simple vitamin B3 derivative, is showing real promise as a practical tool for skin cancer prevention,” said Dr Yousuf Mohammed, a Senior Research Fellow at the University of Queensland. “These findings highlight that timing matters; starting earlier may be the key to stronger protection. For clinicians, the appeal of nicotinamide lies in its accessibility, safety, and tolerability. Unlike systemic retinoids or invasive field therapies, nicotinamide is inexpensive, over-the-counter, and free from significant side effects.

“Overall, these results reinforce what many dermatologists have long suspected, nicotinamide is an underutilized, low-risk intervention that can make a difference in reducing skin cancer burden, especially for patients with an early history of disease,” he added.

The research was published in the journal JAMA Dermatology.

Source: Vanderbilt University Medical Center